We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Shattuck Labs Inc | NASDAQ:STTK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.09 | 2.03% | 4.52 | 4.50 | 4.55 | 4.59 | 4.50 | 4.54 | 7,835 | 15:04:50 |
Presentation Details
Conference: Cowen’s 6th Annual IO Next SummitFormat: Fireside chat with covering analyst Marc Frahm, Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: November 11, 2022Time: 11:40 a.m. ET
Conference: 5th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat with covering analyst Jonathan Miller, Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: November 29, 2022Time: 1:00 p.m. ET
Conference: 34th Annual Piper Sandler Healthcare ConferenceFormat: Corporate PresentationPresenter: Andrew Neill, M.B.A., Shattuck’s Chief Financial OfficerDate: December 1, 2022Time: 11:10 a.m. ET
A live webcast of the fireside chats and presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com
1 Year Shattuck Labs Chart |
1 Month Shattuck Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions